The closing price of Intellia Therapeutics Inc. (NASDAQ: NTLA) was $38.53 for the day, up 7.39% from the previous closing price of $35.88. In other words, the price has increased by $+2.65 from its previous closing price. On the day, 1673160 shares were traded. NTLA stock price reached its highest trading level at $38.70 during the session, while it also had its lowest trading level at $35.47.
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.60 and its Current Ratio is at 6.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on January 24, 2023, Upgraded its rating to Neutral and sets its target price to $39 from $48 previously.
On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $84.Morgan Stanley initiated its Overweight rating on October 11, 2022, with a $84 target price.
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 when Sepp-Lorenzino Laura sold 2,330 shares for $38.48 per share. The transaction valued at 89,659 led to the insider holds 17,629 shares of the business.
BASTA JAMES sold 1,138 shares of NTLA for $42,345 on Jan 04. The EVP, General Counsel now owns 19,559 shares after completing the transaction at $37.21 per share. On Jan 04, another insider, Sepp-Lorenzino Laura, who serves as the EVP, Chief Scientific Officer of the company, sold 2,508 shares for $37.21 each. As a result, the insider received 93,323 and left with 19,959 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 61.31 while its Price-to-Book (P/B) ratio in mrq is 3.55.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $104.87, while it has fallen to a 52-week low of $32.44. The 50-Day Moving Average of the stock is 41.30, while the 200-Day Moving Average is calculated to be 52.03.
NTLA traded an average of 1.15M shares per day over the past three months and 1.14M shares per day over the past ten days. A total of 76.05M shares are outstanding, with a floating share count of 75.75M. Insiders hold about 6.27% of the company’s shares, while institutions hold 80.40% stake in the company. Shares short for NTLA as of Oct 13, 2022 were 6.58M with a Short Ratio of 6.63M, compared to 6.68M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.66% and a Short% of Float of 9.95%.
The firm’s stock currently is rated by 25 analysts. On average, analysts expect EPS of -$1.28 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$1.56, while EPS last year was -$0.97. The consensus estimate for the next quarter is -$1.3, with high estimates of $0.2 and low estimates of -$1.8.
Analysts are recommending an EPS of between -$4.14 and -$6.49 for the fiscal current year, implying an average EPS of -$5.89. EPS for the following year is -$5.91, with 25 analysts recommending between -$4.27 and -$8.24.
A total of 26 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $76M, while the lowest revenue estimate was $25.3M, resulting in an average revenue estimate of $49.11M. In the same quarter a year ago, actual revenue was $33.05M, up 48.60% from the average estimate.